Introduction {#Sec1}
============

In December 2019, a novel coronavirus-infected pneumonia, called coronavirus disease 2019 (COVID-19), occurred in the city of Wuhan, China, related to Huanan Seafood Market \[[@CR1]--[@CR3]\]. This outbreak has spread exponentially throughout the world and is declared a pandemic \[[@CR4]\]*.* The most prevalent clinical symptoms of COVID-19 patients are fever, followed by cough, fatigue, and dyspnea. It can lead to acute respiratory distress syndrome, acute renal failure, shock, and death \[[@CR3], [@CR5]\].

The diagnostic criteria of COVID-19 pneumonia are laboratory evaluation of respiratory secretions acquired from endotracheal aspirate, bronchoalveolar lavage, or nasopharyngeal/ oropharyngeal swab \[[@CR6]\]. Currently, laboratory examination such as reverse transcriptase-polymerase chain reaction (RT-PCR) test has become the standard assessment for the diagnosis of COVID-19 infection \[[@CR7], [@CR8]\]. However, RT-PCR testing results may be falsely negative due to insufficient specimen or laboratory error \[[@CR9]\]. In addition, although the image finding can be positive in the early stages of the disease, RT-PCR results can be negative at the early stages in some cases. However, RT-PCR can become positive in the following course of the disease \[[@CR10], [@CR11]\]. Therefore, a combination of repeated swab tests and CT imaging can be used as a tool to diagnose the individual with negative RT-PCR screening and high suspicion of COVID-19 infection \[[@CR10]\].

Chest CT scan provides more detailed information about the chest and hence, it is used to diagnose COVID-19 patients. In a study using 1014 patients, the sensitivity of chest CT in suggesting COVID-19 based on the positive RT-PCR is 97%, and patients with negative RT-PCR and chest CT findings of 75% are positive \[[@CR12]\]. Abnormal CT findings such as pneumonia, the existence of patterns like ground-glass opacity (GGO), and bilateral patchy shadowing are frequently observed in positive COVID-19 cases \[[@CR13]\]. The most frequent CT features of COVID-19 pneumonia are GGO, crazy-paving pattern, mixed GGO and consolidation, bilateral lobe involvement, and subpleural lesions \[[@CR14], [@CR15]\].

Radiologists can help in several ways in this current pandemic such as (i) early detection of the disease and plan ahead for proper management in later stages of the disease; (ii) score the severity of the disease and help to identify the chance of developing ARDS and the need to transferring to the intensive care unit; and (iii) detect possible secondary or co-infection of bacterial pneumonia, which is very critical as bacterial pneumonia can lead to serious complications \[[@CR16]\]. However, both COVID-19 virus and other non-COVID-19 viruses can cause pneumonia and differentiate them, which is challenging for radiologists as both CT findings look similar \[[@CR15], [@CR17]\]. Bai et al \[[@CR18]\] showed that seven radiologists can diagnose COVID-19 pneumonia with mean sensitivity and specificity of 70.42% and 83.71%, respectively. Also, they concluded that the radiologists showed high specificity but moderate sensitivity in distinguishing COVID-19 pneumonia from other atypical and viral (non-COVID-19) pneumonia based on chest CT findings. To overcome these limitations and manage the COVID-19 pneumonia patients effectively, a computer-aided diagnosis (CAD) system is needed \[[@CR19]\].

Nowadays, CAD systems can help and allow radiologists to make a better decision, especially in CT lung imaging \[[@CR20]--[@CR22]\]. It also help to detect lung abnormalities \[[@CR23], [@CR24]\] and pulmonary fibrosis \[[@CR25], [@CR26]\], manage lung nodules \[[@CR27], [@CR28]\], and differentiate nodules from interferential vessels \[[@CR29], [@CR30]\]. In this work, we have investigated the potential of using the CAD system to diagnose and manage patients with COVID-19 pneumonia disease. In this work, we proposed a clinical CAD system, namely COVIDiag, to differentiate COVID-19 from non-COVID-19 pneumonia diseases using features extracted from the chest CT images. We feel that the proposed system can help to reduce the workload and improve the quality of COVID-19 disease diagnosis.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

Regardless of demographic values like age and gender in the pandemic of the COVID-19, the patients with flu-like symptoms and diagnosed with novel coronavirus were enrolled for the study. A chest high-resolution CT (HRCT) examination was conducted for all patients before enrolling them in this study. The confirmation for COVID-19 was done through RT-PCR based on nasopharyngeal swab samples. The patients with respiratory infections with negative RT-PCR and confirmed laboratory test were excluded in this study. Also, those cases with chronic lung diseases and subsequent pulmonary involvement were excluded. HRCT images of patients with other causes of atypical and viral pneumonia, such as adenoviral or H1N1 flu from PACS of our university hospital, were retrospectively investigated from January 2018 to December 2019.

Image acquisition {#Sec4}
-----------------

All HRCT examinations were performed using a 16-MDCT scanner (Alexion, Canon Medical Systems) with high-resolution protocol: patients in the recumbent situation with the arms over the head; 1- to 2-mm slice thickness in increments of up to 10 mm from the lung apices through the hemidiaphragm, at deep inspiration; tube voltage, 120 kVp; tube current time, 50--100 mAs; and pitch, 0.8--1.5. Parenchymal window settings were set for all patients to a range of window level and a window width of − 600 to − 500 Hounsfield units (HU) and 1500 to 1600 HU, respectively. All of the CT slices were reconstructed using an iterative algorithm (adaptive iterative dose reduction using three-dimensional processing (AIDR 3D)) with the kernel FC56, and scans were acquired without the use of contrast agent.

CT feature extraction {#Sec5}
---------------------

Few studies indicated that the pattern, location, and distribution of lesions can differentiate COVID-19 from other non-COVID-19 pneumonia \[[@CR14], [@CR18], [@CR31]\]. There are few radiological features such as GGO, crazy-paving, peripheral, both peripheral and central involvement, and upper lobe involvement, which are more common in COVID-19 pneumonia compared with non-COVID-19 pneumonia. On the other hand, there are few other radiological features that are more common and specific in non-COVID-19 pneumonia compare with that in COVID-19 pneumonia, such as pleural effusion, pleural thickening, air bronchogram, consolidation, central involvement, and lymphadenopathy.

In this study, two radiologists with more than 15 years of experience in thoracic imaging, who were blinded to the laboratory test, reviewed the CT images. Radiological features were extracted by one radiologist and confirmed by another experienced radiologist. In total, 20 radiological features are extracted for both the groups. These radiological features are as follows:Location 1, location of lesion(s) are evaluated if they involve unilateral, bilateral, or both unilateral and bilateral;Location 2, location of lesion(s) are studied if they are present in lower, upper, or both lobes;Distribution of lesion(s) are defined as peripheral, central, or both central and peripheral;Number lesion(s) is assigned as a single lesion, if there is only one patch of a lesion, multiple lesions, if there are 2--4 patches of lesions in every lung, and diffuse lesion, if lesions involved the entire lobe bilaterally;GGO, which is hazy augmented lung attenuation with the maintenance of bronchial and vascular borders. In other words, a hazy opacity that does not obscure the underlying pulmonary vessel;Consolidation, which is described as opacification with obscuration of vessels and airway borders walls. It is defined as filling of air that usually fills the small airways with something else;Presence of reticular: every thin linear opacity between 1 and 3 mm thickness;Nodule, which is defined as every round or oval well-defined margin opacity;Vascular thickening;Septal thickening;Bronchial wall thickening;Air bronchogram; which is defined as opacification of surrounding alveoli (gray/white) make the air-filled bronchi (dark) detectable;Cavity;Cyst;Crazy-paving, which is a linear pattern superimposed on an area of GGO, with irregular paving stones pattern;Halo sign;Reversed halo sign;Pleural effusion, defined as blunting of the costophrenic angle, cardiophrenic angle, and fluid within the horizontal or oblique fissures;Pleural thickening; andLymphadenopathy, described as a lymph node with a greater size than 1 cm in short axis.

Machine learning study {#Sec6}
----------------------

The MATLAB software (version R2019b, MathWorks Inc) was used to implement machine-learning process. In order to perform an automated diagnosis of COVID-19 cases, five classifiers are used: decision tree, *K*-nearest neighbor (KNN), 3- naïve Bayes, support vector machine (SVM), and ensemble. The optimization method based on the Bayesian optimization algorithm \[[@CR32]\] is used to define the optimized hyperparameters. This method searches the specific hyperparameters within their ranges for each classifier to find the *bestpoint hyperparameters* to yield the highest classification performance. The names of hyperparameters and their ranges (in parentheses) for each classifier are as follows: decision tree: maximum number of splits (1--487), split criterion (Gini's diversity index, maximum deviance reduction); KNN: number of neighbors (1--244), distance metric (city block, Chebyshev, correlation, cosine, Euclidean, Minkowski, Mahalanobis, spearman, hamming, and Jaccard), distance weight (equal, inverse, squared inverse); naïve Bayes: distribution name (Gaussian, kernel), kernel type (Gaussian, box, Epanechnikov, triangle); SVM: kernel function (Gaussian, linear, quadratic, cubic), kernel scale (0.001--1000) and box constraint level (0.001 to 1000); and Ensemble: ensemble method (AdaBoost, RUSBoost, LogitBoost, GentleBoost, and bag), maximum number of splits (1--487), number of learners (10--500), learning rate (0.001--1).

In this study, the entire database is divided into two parts: 80% for training and 20% for testing. All *five* classifiers are trained for 30 iterations using the Bayesian optimization algorithm. The *K*-fold (*K* = 20) cross-validation strategy is used to prevent over-fitting of the models. At the end of the training process, optimization algorithm returns the *bestpoint hyperparameters* for each classifier.

Statistical analysis {#Sec7}
--------------------

The discrimination between COVID-19 and non-COVID-19 groups of CT features is evaluated with the chi-square test. Statistically significant features have a *p* value of less than 0.05.

### Performance evaluation of networks {#Sec8}

Five parameters namely sensitivity, specificity, accuracy, PPV, and NPV are calculated in our study to compare the performance of radiologists and classifiers. COVID-19 and other viral pneumonia (non-COVID-19 group) cases are considered positive and negative, respectively. Therefore, correctly diagnosed COVID-19 and non-COVID-19 cases are indicated as *N*~*TP*~ and *N*~*TN*~, respectively. Also, incorrectly diagnosed COVID-19 and non-COVID-19 cases are identified as *N*~*FP*~ and *N*~*FN*~, respectively. Furthermore, ROC curve analysis is used and AUC is computed \[[@CR33]\]. SPSS software (version 24.0, IBM Corporation) is used for statistical analysis. Figure [1](#Fig1){ref-type="fig"} shows the steps involved in our study at a glance.Fig. 1An overview of the six main steps used in this study

Results {#Sec9}
=======

In this study, 612 patients (306 COVID-19 and 306 non-COVID-19) were recruited. In total, 488 patients (with 50--50 distribution) were used for the training phase and the rest of the patients (20%) were used to test the developed model. Figure [2](#Fig2){ref-type="fig"} shows the sample CT images of patients with COVID-19 and non-COVID-19 pneumonia.Fig. 2CT sample images of patients with pneumonia. **a** A 28-year-old male with confirmed COVID-19 pneumonia. The red arrow in the right upper lobe indicates mixed ground glass and crazy paving opacity. **b** A 67-year-old female patient with confirmed COVID-19 pneumonia. The red arrows indicate multifocal ground-glass opacity pattern in both lobes. **c** An 68-year-old male patient with atypical pneumonia. The red arrows indicate mixed ground glass and alveolar consolidation pattern in the right lower lobe. **d** A 67-year-old male patient with H1N1 pneumonia. The red and yellow arrows indicate alveolar consolidation the right and left upper lobe, respectively

CT findings {#Sec10}
-----------

The bilateral involvement is significantly high in COVID-19 patients (176 out of 244, 72.13%) compared with that in the non-COVID-19 group (72 out of 244, 29.5%). In the location 2 feature, the infection involvement of the upper, lower, and both lobes in COVID-19 group is observed in 106 (43.44%), 48 (19.67%), and 90 (36.89%) patients, respectively, which are significant differences compared with the non-COVID-19 group whose involvements are observed in 131 (53.69%), 89 (36.47%), and 24 (09.84%) cases, respectively. The peripheral, central, and both central and peripheral involvements in COVID-19 group are discovered in 147 (60.25%), 26 (10.65%), and 71 (29.10%) cases, respectively, for the distribution feature, which have shown significant differences compared with the non-COVID-19 group whose the involvements are observed in 41 (16.80%), 115 (47.13%), and 88 (36.07%) cases, respectively (Table [1](#Tab1){ref-type="table"}).Table 1CT chest findings of COVID-19 and non-COVID-19 groupsCT findingsCOVID-19 (*n* = 244)Non-COVID-19 (*n* = 244)*p* valueLocation 1\< 0.001  Unilateral68 (27.87)172 (70.49)  Bilateral176 (72.13)72 (29.50)Location 2\< 0.001  Lower lobe106 (43.44)131 (53.69)  Upper lobe48 (19.67)89 (36.47)  Both lobes90 (36.89)24 (09.84)Distribution\< 0.001  Peripheral147 (60.25)41 (16.80)  Central26 (10.65)115 (47.13)  Both central and peripheral71 (29.10)88 (36.07)Lesion\< 0.001  Single32 (13.11)155 (63.52)  Multiple136 (55.74)74 (30.33)  Diffuse76 (31.15)15 (06.15)GGO\< 0.001  No67 (27.46)227 (93.03)  Yes177 (72.54)17 (06.97)Consolidation\< 0.001  No143 (58.61)39 (15.98)  Yes101 (41.39)205 (84.02)Reticular\< 0.001  No242 (99.18)198 (81.15)  Yes2 (0.82)46 (18.85)Nodule\< 0.001  No244 (100)213 (87.30)  Yes0 (0.0)31 (12.70)Vascular thickening0.499  No244 (100)242 (99.18)  Yes0 (0.0)2 (0.82)Septal thickening0.511  No208 (85.25)213 (87.30)  Yes36 (14.75)31 (12.70)Bronchial wall thickening\< 0.001  No242 (99.18)216 (88.52)  Yes2 (0.82)28 (11.48)Air bronchogram\< 0.001  No230 (94.26)178 (72.95)  Yes14 (05.74)66 (27.05)Cavity\< 0.001  No244 (100)232 (95.08)  Yes0 (0.0)12 (04.92)Cyst1.000  No244 (100)243 (99.59)  Yes0 (0.0)1 (0.41)Crazy paving\< 0.001  No197 (80.74)240 (98.36)  Yes47 (19.26)4 (01.64))Halo Sign0.787  No236 (96.72)238 (97.54)  Yes8 (03.28)6 (02.46)Reversed halo sign-  No244 (100)244 (100)  Yes0 (0)0 (0)Pleural effusion0.005  No233 (95.49)216 (88.52)  Yes11 (04.51)28 (11.48)Pleural thickening\< 0.001  No244 (100)226 (92.62)  Yes0 (0)18 (07.38)Lymphadenopathy\< 0.001  No243 (99.59)222 (09.98)  Yes1 (0.41)22 (09.02)Number in parentheses represents the percentage of patients in each group*GGO*, ground-glass opacity

The single, multiple, and diffuse lesions in the COVID-19 group are observed in 32 (13.11%), 136 (55.74%), and 76 (31.15%) cases, respectively, for the lesion feature compared with those in the non-COVID-19 group whose single, multiple, and diffuse lesions are found in 155 (63.52%), 74 (30.33%), and 15 (06.15%) cases, respectively, with *p* value \< 0.001. In addition, the GGO and crazy-paving features are found significantly high in COVID-19 cases compared with those in the non-COVID-19 group (*p* \< 0.001). In contrast, consolidation, reticular, bronchial wall thickening, nodule, air bronchogram, cavity, pleural effusion, pleural thickening, and lymphadenopathy are more common in the non-COVID-19 group. However, no significant differences are seen in other CT features like vascular thickening, septal thickening, cyst, halo sign, and reversed halo sign (Table [1](#Tab1){ref-type="table"}).

Performance of machine learning and radiologist {#Sec11}
-----------------------------------------------

The results of the optimization process and the hyperparameters of each optimized network are shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3The optimization curves of five networks after 30 iterations. **a** Decision tree; **b***K*-nearest neighbor; **c** naïve Bayes; **d** support vector machine; and (**e**) ensemble (named as COVIDiag). During the process, the optimization algorithm seeks different combinations in each iteration to find the condition with the minimum classification error and confidence interval, i.e., "bestpoint hyperparameters"

The classification results of the models for COVID-19 and non-COVID-19 groups are summarized in Table [2](#Tab2){ref-type="table"}. Also, we measured the performance of the radiologist as a baseline to compare the results with these five models. Among all models, the highest performance is obtained for ensemble classifier with an AUC of 0.988 (sensitivity, 94.67%; specificity, 93.03%; accuracy, 93.85%) for the training dataset. In contrast, the lowest performance is obtained for decision tree with an AUC of 0.934 (sensitivity, 89.34%; specificity, 90.16%; accuracy, 89.75%). After training the models, they are tested with blinded (unseen) data. Then, the highest discriminative power is obtained for the ensemble model with AUC, sensitivity, specificity, and accuracy of 0.965, 93.54%, 90.32%, and 91.94%, respectively. Also, the AUC, sensitivity, specificity, and accuracy obtained for the diagnosis by a radiologist are 0.879, 87.10%, 88.71%, and 87.90%, respectively (Table [2](#Tab2){ref-type="table"}). Radar plots and ROC curves for various classifiers and radiologist in the testing phase are presented in Fig. [4a and b](#Fig4){ref-type="fig"}, respectively. The COVIDiag model is available (Link) (to test the model with your own data, please follow the guide sheet (Figure E[1](#MOESM1){ref-type="media"}, Supplementary material).Table 2Performance of five networks and the radiologist in differentiating COVID-19 from non-COVID-19 cases*C* and *NC* stand for COVID-19 and non-COVID-19 cases, respectively; *KNN*, *K*-nearest neighbor; *SVM*, support vector machineFig. 4**a** ROC curves and (**b**) radar plot of five networks and the radiologist on testing blinded dataset

Discussion {#Sec12}
==========

In this study, the best performance is achieved by ensemble classifier (COVIDiag) with an AUC of 0.965. The main advantage of this classifier is that it uses many (81 in this study) learners to build an accurate model. Aggregating the output of the learners help to build a robust model compared to the individual learner \[[@CR34]\]. Hence, the stability and discriminative power of the ensemble classifier is higher than other classifiers used in this study. In addition, our results indicate that the performance of the COVIDiag is even higher than the radiologist for the testing dataset (AUC of COVIDiag vs. radiologist: 0.965 vs. 0.879). In this work, 58 out of 62 COVID-19 cases and 56 out of 62 non-COVID-19 cases are correctly diagnosed by COVIDiag. The details about the diagnosis results of COVIDiag and radiologists are listed in Tables E[1](#MOESM1){ref-type="media"} and E[2](#MOESM1){ref-type="media"} (supplementary material). The machine-learning model can deal with complex and multiparametric data better than the radiologists. During the visual inspection process, radiologists should extract several radiological features from the CT images, make a meaningful relationship between them, and finally make a final decision. This step of processing is subjective, time-consuming, and prone to human errors. Hence, in this study, we proposed a practical clinical CAD system (COVIDiag) to help radiologists during routine practices.

The results of the present study indicate that multiple and diffused lesions with GGO and crazy-paving patterns are significantly more common in COVID-19 pneumonia cases. On the other hand, patients with cavity, nodule, single lesion, consolidation, reticular, bronchial wall thickening, air bronchogram, pleural effusion, pleural thickening, and lymphadenopathy are significantly more likely to have non-COVID-19 pneumonia. Moreover, the bilateral involvements with peripheral distribution occur more significantly in patients with COVID-19 pneumonia. Our findings in terms of distribution, GGO, pleural effusion, and pleural thickening are similar, but the terms of nodule, location 1, bronchial wall thickening, crazy-paving, halo, reverse halo, and vascular thickening are not similar to the study by Bai et al \[[@CR18]\]. In addition, except for GGO, lymphadenopathy, and pleural effusion, the results of other features are similar to those of Long et al \[[@CR31]\] and Cheng et al \[[@CR35]\]. The main reason for the difference in the results is that these studies have used either a small number of patients in both groups or included all types of non-COVID-19 pneumonia patients. Hence, bacterial or other atypical pneumonia cases may be included. On the other hand, during the diagnosing process, radiologists should pay attention to the time of patient's admission (Table [3](#Tab3){ref-type="table"}) and the similar CT findings that can be misdiagnosed as COVID-19 pneumonia (Table [4](#Tab4){ref-type="table"}) to reduce the possible false-positive cases.Table 3CT findings changes related to COVID-19 pneumonia over timePhase of diseaseDays after onset symptomsCharacteristicsEarly0--4GGO, partial crazy-paving pattern, lower number of involved lobes; or have normal CTProgressive5--8Extension of GGO, increased crazy-paving patternPeak10--13ConsolidationAbsorption≥ 14Fibrous stripes, gradual resolution*GGO*, ground-glass opacityTable 4A list of alternative diagnosis for COVID-19 pneumoniaType of diseaseDefinitionCT features suggesting pneumonia of other cause  Pneumonia from bacterial originCharacterized by a lobar or segmental airspace consolidation limited by the pleural surfaces. Ground glass attenuation, centrilobular nodules, and bronchial wall thickening may be other CT findings.  Pneumocystis jiroveci pneumoniaIn immunocompromised patients, GGO within the lung parenchyma is not similar to COVID-19; it is more diffusely distributed, and subpleural sparing is more prominent.  Other viral causesCT features may be problematic, but CT abnormalities in COVID-19 more frequently exhibit a peripheral predominance, and pleural effusion and lymphadenopathy are less frequent.Non-infectious causes of acute GGO  Pulmonary edemaCentral predominance and peripheral sparing of the peripheral portions of the lung are more predominant contrary to COVID-19. Septal lines, pleural effusion, and large pulmonary veins are another suggestive singe.  Goodpasture's syndromeThere is no subpleural predominance contrary to that seen in COVID-19.  Drug-induced pneumonitisSubpleural sparing is more characteristic, and a history of drug exposure helps diagnosis.  Organized pneumoniaSimilar findings with COVID-19 are seen, but GGO occurs in a very different context.*GGO*, ground-glass opacity

Few artificial intelligence studies on chest CT images have been emerging to help physicians to manage patients with COVID-19 pneumonia. Some studies reported that deep learning could diagnose COVID-19 pneumonia cases with an AUC of 0.960 \[[@CR36]\] and 0.994 \[[@CR37]\], respectively. However, we used simple machine-learning technique and achieved an AUC of 0.965. Hence, the COVIDiag is more effective in discriminating COVID-19 pneumonia cases from non-COVID-19 cases. The main advantage of the proposed model is simple and takes less time to train as it is not deep learning--based model.

Another advantage of the COVIDiag is that it is easy to use. After the acquisition of CT images from the patients, we can extract the desired features from the images and feed those features on the pre-trained model to get the output class. In addition, COVIDiag is reproducible and can be used for unlimited time in a day without degrading the performance. These test images again can be used to train the model and make the model more robust. Also, this system is more economical and can be used along with the RT-PCR method. The RT-PCR method is expensive as it involved well-equipped laboratories which many underdeveloped countries may not be able to afford \[[@CR38]\]. In addition, countries continuously need to supply the high demand for the new kits. In the present scenario, our proposed COVIDiag can be used to meet the challenges of third-world countries and help to rehabilitate the affected patients immediately by accurate faster diagnosis.

The limitation of our proposed system is that CT findings can be negative in the early stage, while the RT-PCR is positive \[[@CR39], [@CR40]\]. In this situation, the results of COVIDiag tend to be negative. Another limitation is that, in some cases, the initial results of RT-PCR may be false negative \[[@CR9]\]. So, these patients with COVID-19 may be excluded incorrectly. It should be noted that the PPV and NPV indices are not intrinsic to the test and they depend on the prevalence of diseases. In this study, we provided balanced dataset, which can affect the indices.

Conclusion {#Sec13}
==========

This study proposed an automated clinical COVIDiag system based on routine radiological parameters and machine-learning techniques. The developed tool is simple to operate and can help the radiologists to reduce their daily workload by helping them to make an accurate diagnosis. In the future, we intend to extend our COVIDiag model to assess the severity of COVID-19 patients.
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